

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CLARIFICATION ANNOUNCEMENT
RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

**CHANGE OF COMPANY SECRETARY,
AUTHORISED REPRESENTATIVE AND
AGENT FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND
NOTICES IN HONG KONG**

RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Reference is made to the announcement dated 15 June 2018 of China NT Pharma Group Company Limited (the “**Company**”) in relation to the resignation of Dr. Lap-Chee Tsui (“**Dr. Tsui**”) as an independent non-executive Director and a member of the Audit Committee of the Company (the “**Announcement**”). Unless otherwise stated, capitalised terms in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, Dr. Tsui has resigned as an independent non-executive Director with effect from 15 June 2018, due to personal reasons. The Company hereby clarifies that Dr. Tsui has served as an independent non-executive Director of the Company for over eight years and resigned from the abovementioned positions in order to devote more time on his other personal work commitments.

Save for the above clarification, all information in the Announcement remains the same.

CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND AGENT FOR THE ACCEPTANCE OF SERVICE OF PROCESS AND NOTICES IN HONG KONG

The Board further announces that Mr. Tong Ka Kin Kenneth (“**Mr. Tong**”) tendered his resignation (the “**Resignation**”) as the company secretary, authorised representative (“**Authorised Representative**”) of the Company under the Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Rules 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from 22 June 2018. Mr. Tong confirmed that he has no disagreement with the Board and there are no circumstances related to his Resignation which need to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Company would like to thank Mr. Tong for his contributions to the Company in the past.

The Board is also pleased to announce that Ms. Lai Siu Kuen (“**Ms. Lai**”) has been appointed in replacement of Mr. Tong as the company secretary, Authorised Representative of the Company and the Process Agent with effect from 22 June 2018.

Ms. Lai is an associate director of TMF Hong Kong Limited, which is a corporate secretarial services provider. She has over 18 years of professional and in-house experience in the company secretarial field. She is a fellow member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 22 June 2018

As at the date of this announcement, the executive directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive directors of the Company are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tze Shan Hailson Yu and Dr. Hong Yan.